Highlights

  • Avacta advanced two oncology programs toward clinical development milestones during 2025.
  • The company reported updated efficacy and safety data from its lead oncology candidate.
  • Year-end cash position supports planned research activities into Q3 2026.

Avacta Group plc, (LSE:AVCT), released a trading update outlining operational, clinical, and financial developments for the year ended December 31, 2025. The company continues to focus on advancing its pre|CISION® tumor-activated delivery platform, with two oncology programs expected to be in clinical development during 2026.

During the year, Avacta raised GBP 22.5m through equity funding to support research and development activities. The company also reported progress across its intellectual property portfolio, with additional filings related to sustained-release and dual-payload drug delivery mechanisms.

Faridoxorubicin Data and Ongoing Enrollment
The lead program, faridoxorubicin (AVA6000), continued patient enrollment in Phase 1b expansion cohorts during 2025. Updated data released in December showed a disease control rate of 90% in patients with salivary gland cancer across the full cohort. The expansion cohorts aim to evaluate efficacy across more defined patient populations to support future trial design.

Progression-free survival data from Phase 1a and early Phase 1b observations are being collected to inform the size and structure of potential later-stage trials. Additional clinical data from patients with triple-negative breast cancer are expected in the first half of 2026. Further development of AVA6000 remains linked to partnership discussions as the dataset matures.

FAP-Exd Program Nears Clinical Entry
Avacta also reported new pharmacology data supporting the investigational new drug process for FAP-Exd (AVA6103). The Phase 1 trial design was released, with clinical testing expected to begin in Q1 2026, subject to regulatory clearance.

The planned trial will enroll patients across four tumor types—pancreatic, gastric, small cell lung, and cervical cancers—identified through collaboration with Tempus AI. The study incorporates parallel dosing schedules and a Bayesian Optimal Interval design to support dose optimization and data collection efficiency. Preliminary results from the trial are anticipated in the second half of 2026.

Pipeline Expansion and Financial Position
The company highlighted ongoing development of its dual-payload technology, AVA6207, which enables the release of two therapeutic agents through a single tumor-activated mechanism. Payload selection for this program is planned for 2026.

Financially, Avacta ended 2025 with unaudited cash and cash equivalents of GBP 16.9m, providing operational runway into Q3 2026. During the year, the company also completed the disposal of its non-core diagnostics business and renegotiated terms of its convertible bond, deferring near-term repayments.

Share Performance
AVCT was traded at 53.70 GBX at the time of wring on January 20, declining 3.24%during the day.